Clinical trial registry record

A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 28, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06769048
Last registry update
July 28, 2026
Status
Active Not Recruiting
Phase
Phase 2
Sponsor
Boehringer Ingelheim
Enrollment
150
Countries
United States, Puerto Rico
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
150
Population
ALL · 50 Years
Duration
2025-01-31 to 2027-01-05
Intervention
Placebo-matching BI 1584862; BI 1584862
Comparator
Placebo-matching BI 1584862
Outcomes measured
Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluores…; Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a…; Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a tria…; Occurrence of TEAES from drug administration until Week 52 — Up to week 52.; Change from baseline in partial attenuation as a percentage of the ellipsoid zone (EZ) at the macular area with thickne…; Change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FA…; Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at lea…; Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON